Inhibrx Biosciences Inc.

NASDAQ: INBX · Real-Time Price · USD
23.42
-0.52 (-2.17%)
At close: Aug 15, 2025, 12:51 PM

Inhibrx Biosciences Cash Flow Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net Income
1.69B -239.73M -145.23M -81.77M
Depreciation & Amortization
2.29M 1.19M 1.23M 1.2M
Stock-Based Compensation
58.52M 24.85M 20.45M 15.05M
Other Working Capital
33.77M 13.76M 3.74M -1.67M
Other Non-Cash Items
-1.99B 5.03M 5.09M 2.73M
Deferred Income Tax
n/a n/a n/a -9K
Change in Working Capital
52.05M 15.35M 3.16M -17.52M
Operating Cash Flow
-194.41M -193.31M -115.3M -80.32M
Capital Expenditures
-2.6M -4.59M -686K -864K
Cash Acquisitions
n/a n/a n/a 55K
Purchase of Investments
n/a n/a n/a n/a
Sales Maturities Of Investments
n/a n/a n/a n/a
Other Investing Acitivies
n/a n/a n/a n/a
Investing Cash Flow
-2.6M -4.59M -686K -809K
Debt Repayment
n/a n/a n/a n/a
Common Stock Repurchased
n/a n/a n/a n/a
Dividend Paid
n/a n/a n/a n/a
Other Financial Acitivies
n/a n/a 128.81M 83.77M
Financial Cash Flow
71.68M 201.96M 258.55M 83.77M
Net Cash Flow
-125.33M 4.06M 142.56M 2.64M
Free Cash Flow
-197.01M -197.9M -115.99M -81.19M